Approval of New Breast Cancer Treatment Despite Expert Panel Concerns

Introduction

The FDA has recently granted accelerated approval for camizestrant (Etcamah), a novel oral selective estrogen receptor degrader (SERD), specifically for treating hormone receptor-positive/HER2-negative breast cancer in patients where resistance mutations of ESR1 are detected during first-line therapy. This approval marks a significant development in the management of breast cancer.

Switching Therapy Based on Biomarkers

This new treatment strategy enables clinicians to switch therapies not solely based on traditional radiographic progression but also by detecting resistance mutations in circulating tumor DNA (ctDNA) in the blood. This approach has sparked debate as it contrasts with the recommendations from the FDA’s external advisors.

Need for Confirmatory Studies

Although the FDA has approved this therapy, they require confirmatory studies to ensure the clinical benefit of this intervention before disease progression is established, as the benefits of early intervention are still under investigation.

Trial Results and Improvements in Patient Outcomes

The approval was based on data from the SERENA-6 trial, where replacing the aromatase inhibitor (AI) with camizestrant upon detection of ESR1 mutations led to a 56% reduction in the risk of disease progression or death. Median progression-free survival improved significantly from 9.2 months on AI to 16 months with the SERD.

Expert Opinions and Potential Risks

Despite these promising results, there were concerns from FDA panelists regarding the clarity of the clinical benefit linked to the early switch of therapy based solely on ESR1 mutations, highlighting that the overall survival data was not yet robust. The combination therapy does carry common adverse effects such as visual disturbances and fatigue, and is also warned against in the presence of certain drugs that may prolong the QTc interval.

Conclusion and Diagnostic Tools

In conjunction with the drug approval, the FDA has also accepted the Guardant360 CDx assay as a diagnostic tool to help identify patients eligible for this innovative treatment, which is a significant step towards personalized medicine in oncology.

Disclaimer: The information provided is for educational purposes only and should not be considered as medical advice. Always consult with a healthcare professional for medical concerns and treatment options.

Fuente: https://www.medpagetoday.com/hematologyoncology/breastcancer/122920

Fuente primaria: FDA — Accelerated approval of camizestrant (Etcamah), based on the SERENA-6 trial (NCT04964934)